Kangtai Biotech announced that the quadrivalent influenza virus lysis vaccine developed by the company has completed preparations for phase I clinical trials, started phase I clinical trials, and recently successfully completed the enrollment of the first test subjects. The vaccine is suitable for people aged 6-35 months. It can stimulate the body to develop immunity against influenza viruses, and is used to prevent influenza caused by vaccine-related influenza viruses. The quadrivalent influenza virus lysis vaccine, which has begun phase I clinical trials, uses a single-center, randomized, blinded, positive control design to evaluate the safety and initial immunogenicity of the vaccine in people aged 6-35 months.

Kangtai Biotech announced that the quadrivalent influenza virus lysis vaccine developed by the company has completed preparations for phase I clinical trials, started phase I clinical trials, and recently successfully completed the enrollment of the first test subjects. The vaccine is suitable for people aged 6-35 months. It can stimulate the body to develop immunity against influenza viruses, and is used to prevent influenza caused by vaccine-related influenza viruses. The quadrivalent influenza virus lysis vaccine, which has begun phase I clinical trials, uses a single-center, randomized, blinded, positive control design to evaluate the safety and initial immunogenicity of the vaccine in people aged 6-35 months.